GlassScriptPhysician profile
Asad Mehdi
NPI 1578779898
$13,393.68
in general payments reported to CMS, 2019-2025
33 companies · $3,256 in 2025
The $3,256 reported for 2025 was more than what 93% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,510 · 2020: $460 · 2021: $1,285 · 2022: $1,752 · 2023: $2,653 · 2024: $2,478 · 2025: $3,256.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,333 · Education: $54.29.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,332.84 |
| Education | $54.29 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,902.04 | 2021-2025 | |
| Janssen Pharmaceuticals, INC | $1,328.49 | 2019-2025 | Invega Sustenna, Invega Trinza, Spravato |
| Otsuka America Pharmaceutical, INC. | $1,240.59 | 2019-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Lundbeck LLC | $1,228.97 | 2019-2025 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Alkermes, INC. | $1,175.40 | 2019-2025 | Aristada, Lybalvi |
| Teva Pharmaceuticals USA, INC. | $1,064.80 | 2019-2025 | Uzedy, Austedo Xr, Austedo Xr |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $972.45 | 2021-2025 | Caplyta |
| Takeda Pharmaceuticals U.S.A., INC. | $954.21 | 2019-2025 | Trintellix |
| Neurocrine Biosciences, INC. | $621.03 | 2020-2025 | Ingrezza |
| Sunovion Pharmaceuticals INC. | $375.78 | 2019-2022 | |
| Noven Therapeutics, LLC | $356.98 | 2020-2025 | Secuado, Xelstrym |
| Corium, LLC | $284.97 | 2022-2025 | Azstarys |
| Supernus Pharmaceuticals, INC. | $261.82 | 2022-2025 | Qelbree, Qelbree |
| Vanda Pharmaceuticals INC. | $228.18 | 2020-2025 | Fanapt |
| E.R. Squibb & Sons, L.L.C. | $207.11 | 2024-2025 | Cobenfy |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch Health US, LLC | $185.73 | 2021-2025 | Aplenzin, Wellbutrin |
| Tris Pharma INC | $172.86 | 2023-2025 | Dyanavel Xr |
| Almatica Pharma LLC | $158.29 | 2022-2025 | Loreev Xr |
| Orexo US, INC. | $105.80 | 2019-2024 | Zubsolv |
| Shire North American Group INC | $90.54 | 2019 | |
| Neos Therapeutics, LP | $90.45 | 2021-2024 | Adzenys Xr-Odt |
| Idorsia Pharmaceuticals US INC | $57.24 | 2023-2024 | Quviviq |
| Ironshore Pharmaceuticals INC. | $46.63 | 2019-2020 | |
| Axsome Therapeutics, INC. | $42.21 | 2025 | Auvelity |
| Neuronetics, INC. | $38.24 | 2019-2020 | |
| Allergan, INC. | $35.21 | 2019-2020 | |
| Janssen Biotech, INC. | $35.00 | 2025 | Simponi Aria, Tremfya |
| Indivior INC. | $25.23 | 2022 | |
| Bioxcel Therapeutics, INC. | $24.20 | 2023 | Igalmi |
| Jazz Pharmaceuticals INC. | $23.28 | 2022 | |
| Masimo Corporation | $21.49 | 2023 | Emma and Isa |
| Lilly USA, LLC | $19.99 | 2025 | Zepbound |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $18.47 | 2024 | Rexulti, Abilify Maintena |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Asad Mehdi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.